Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
ThrombosisAcute Ischemic Stroke (AIS)
Interventions
DRUG

Intravenous thrombolysis (alteplase and other guideline-recommended thrombolytic agents)

Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg),intravenous Tenecteplase(0.25mg/kg,administered as a single intravenous bolus injection over 5 - 10 seconds,with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).

Trial Locations (1)

Unknown

Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER